

# Breast Cancer<sup>®</sup>

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

**FACULTY INTERVIEWS**

Kimberly L Blackwell, MD

Erin Duff, MSN, ANP-BC

Kathy D Miller, MD

Christina M Brown, RN, BSN

Hope S Rugo, MD

*Additional comments by  
three women with breast cancer*

**EDITOR**

Neil Love, MD



---

## *Breast Cancer Update for Nurses*

### A Continuing Nursing Education Audio Series

---

#### OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances, the efficacy of new agents and regimens and strategies to minimize and manage associated toxicities. This program provides nurses with access to the latest research developments in systemic therapy and the opinions of oncology nurses and clinical investigators with experience and expertise in the field, in addition to perspectives of patients undergoing treatment.

#### PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

#### EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Describe the evidence-based benefits and risks associated with systemic therapies, including chemotherapy, PARP inhibitors and endocrine and biologic agents, used in the treatment of breast cancer in the neoadjuvant, adjuvant and metastatic settings.
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
- Explain the advantages and limitations of available genomic assays to quantify recurrence risk and aid in adjuvant treatment decisions.
- Discuss the psychosocial and emotional needs of patients and their loved ones, in addition to healthcare professionals, associated with the diagnosis and management of breast cancer.

#### ACCREDITATION STATEMENTS

This educational activity for 2.5 contact hours is provided by Research To Practice during the period of July 2010 through July 2011.

Research To Practice is an approved provider of continuing nursing education by the NJSNA, an accredited approver, by the American Nurses Credentialing Center's Commission on Accreditation.

#### HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website [ResearchToPractice.com/BCUN110](http://ResearchToPractice.com/BCUN110) also includes links to relevant abstracts and full-text articles.

The Post-test and Educational Assessment and Credit Form may be completed in this book and either mailed to Research To Practice, One Biscayne Tower, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

*This program is supported by educational grants from Genentech BioOncology and Genomic Health Inc.*

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at [Info@ResearchToPractice.com](mailto:Info@ResearchToPractice.com), call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

## Breast Cancer®

U P D A T E

## FACULTY AFFILIATIONS



**Kimberly L. Blackwell, MD**  
Associate Professor of Medicine  
Assistant Professor of Radiation  
Oncology, Duke University  
Medical Center  
Durham, North Carolina



**Christina M. Brown, RN, BSN**  
Breast Cancer Research Nurse  
Indiana University  
School of Medicine  
Indianapolis, Indiana



**Erin Duff, MSN, ANP-BC**  
Nurse Practitioner  
Duke University Medical Center  
Durham, North Carolina



**Hope S. Rugo, MD**  
Clinical Professor of Medicine  
Director, Breast Oncology and  
Clinical Trials Education  
University of California, San  
Francisco, Helen Diller Family  
Comprehensive Cancer Center  
San Francisco, California



**Kathy D. Miller, MD**  
Sheila D Ward Scholar of  
Medicine; Associate Professor  
of Medicine, The Indiana  
University Melvin and  
Bren Simon Cancer Center  
Indianapolis, Indiana

## CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — **Ms Duff** and **Ms Brown** had no real or apparent conflicts of interest to disclose. **Dr Blackwell** — Consulting Agreements and Speakers Bureau: GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Paid Research: Abraxis BioScience, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline. **Dr Miller** — Advisory Committee: Genentech BioOncology, MethylGene Inc, Roche Laboratories Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. **Dr Rugo** — Speakers Bureau: AstraZeneca Pharmaceuticals LP.

**EDITOR** — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

**Breast Cancer Update for Nurses — Issue 1, 2010****QUESTIONS (PLEASE CIRCLE ANSWER):**

- Data show that the risk of breast cancer recurrence is \_\_\_\_\_ when chemotherapy is administered prior to lumpectomy or mastectomy (neoadjuvant) in comparison to after surgery (adjuvant).**
  - Significantly greater
  - Significantly less
  - Unchanged
- Researchers from MD Anderson Cancer Center, led by Ana Maria Gonzalez-Angulo, reported that women with small, HER2-positive breast tumors have a \_\_\_\_\_ prognosis compared to women with similar-sized HER2-negative tumors.**
  - Worse
  - Better
  - Equivalent
- When a patient has a positive tumor response to neoadjuvant docetaxel/carboplatin/trastuzumab (TCH), trastuzumab is generally continued after surgery for a total duration of \_\_\_\_\_.**
  - Three months
  - Six months
  - Nine months
  - 12 months
- When patients are receiving adjuvant trastuzumab for HER2-positive breast cancer, cardiac monitoring \_\_\_\_\_ indicated.**
  - Is
  - Is not
- In the assessment of patients with treatment-induced febrile neutropenia, which of the following are indicators that the patient may require hospitalization?**
  - Dehydration requiring fluids
  - Pneumonia
  - Advanced age
  - All of the above
- In the TAILORx study, patients with an intermediate Recurrence Score® according to the Oncotype DX® assay are randomly assigned to receive endocrine therapy with or without \_\_\_\_\_.**
  - Bevacizumab
  - Chemotherapy
  - Lapatinib
  - Trastuzumab
- Which genomic assay requires fresh-frozen tumor specimens?**
  - Oncotype DX
  - MammaPrint®
  - Both a and b
  - Neither a nor b
- Though the Oncotype DX assay has been integrated into the clinical management of node-negative tumors, recent data have emerged suggesting its potential utility in the management of node-positive tumors.**
  - True
  - False
- In ECOG-E2100, a Phase III trial evaluating first-line chemotherapy with or without bevacizumab for metastatic breast cancer, progression-free survival was \_\_\_\_\_ for patients who received bevacizumab compared to those who did not.**
  - Significantly longer
  - Significantly shorter
  - Equivalent
- Potential side effects of bevacizumab include which of the following?**
  - Hand-foot syndrome
  - Hypertension
  - Wound-healing impairment
  - Both b and c

**Breast Cancer Update for Nurses — Issue 1, 2010**

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

**PART ONE — Please tell us about your experience with this educational activity**

**How would you characterize your level of knowledge on the following topics?**

4 = Excellent    3 = Good    2 = Adequate    1 = Suboptimal

	BEFORE	AFTER
Risk of recurrence in patients with small, node-negative, HER2-positive early breast cancer	4 3 2 1	4 3 2 1
Assessment and care of patients with treatment-induced febrile neutropenia	4 3 2 1	4 3 2 1
Tolerability and side effects of bevacizumab	4 3 2 1	4 3 2 1
Role of OncoType DX for patients with node-positive breast cancer	4 3 2 1	4 3 2 1

**Has the activity unfairly influenced you toward a particular product or service?**

Yes     No

If yes, then describe what was presented: .....

.....

.....

.....

**Will this activity help you improve patient care?**

Yes     No     Not applicable

If yes, how will it help you improve patient care? .....

.....

.....

.....

**Did the activity meet your educational needs and expectations?**

Yes     No

If no, please explain: .....

.....

.....

.....

**Please respond to the following learning objectives (LOs) by circling the appropriate selection:**

4 = Yes    3 = Will consider    2 = No    1 = Already doing    N/M = LO not met    N/A = Not applicable

**As a result of this activity, I will be able to:**

- Describe the evidence-based benefits and risks associated with systemic therapies, including chemotherapy, PARP inhibitors and endocrine and biologic agents, used in the treatment of breast cancer in the neoadjuvant, adjuvant and metastatic settings. . . . . 4 3 2 1 N/M N/A
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment. . . . . 4 3 2 1 N/M N/A
- Explain the advantages and limitations of available genomic assays to quantify recurrence risk and aid in adjuvant treatment decisions. . . . . 4 3 2 1 N/M N/A
- Discuss the psychosocial and emotional needs of patients and their loved ones, in addition to healthcare professionals, associated with the diagnosis and management of breast cancer. . . . . 4 3 2 1 N/M N/A

**EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)**

**What other practice changes will you make or consider making as a result of this activity?**

**What additional information or training do you need on the activity topics or other oncology-related topics?**

**Additional comments about this activity:**

**As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.**

- Yes, I am willing to participate in a follow-up survey.
- No, I am not willing to participate in a follow-up survey.

**PART TWO — Please tell us about the faculty and editor for this educational activity**

	4 = Excellent	3 = Good	2 = Adequate	1 = Suboptimal	
<b>Faculty</b>	<b>Knowledge of subject matter</b>				<b>Effectiveness as an educator</b>
Kimberly L Blackwell, MD	4	3	2	1	4 3 2 1
Erin Duff, MSN, ANP-BC	4	3	2	1	4 3 2 1
Kathy D Miller, MD	4	3	2	1	4 3 2 1
Christina M Brown, RN, BSN	4	3	2	1	4 3 2 1
Hope S Rugo, MD	4	3	2	1	4 3 2 1
<b>Editor</b>	<b>Knowledge of subject matter</b>				<b>Effectiveness as an educator</b>
Neil Love, MD	4	3	2	1	4 3 2 1

**Please recommend additional faculty for future activities:**

**Other comments about the faculty and editor for this activity:**

**REQUEST FOR CREDIT — Please print clearly**

Name: ..... Specialty: .....

Credentials:

- MD     DO     PharmD     NP     CNS     RN
- PA     Other.....

Street Address: ..... Box/Suite: .....

City, State, Zip: .....

Telephone: ..... Fax: .....

Email: .....

Signature: ..... Date: .....

BCUN110

**To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at [www.ResearchToPractice.com/BCUN110](http://www.ResearchToPractice.com/BCUN110).**

# Breast Cancer®

U P D A T E

<b>Editor</b>	Neil Love, MD
<b>Managing Editor and CME Director</b>	Kathryn Ault Ziel, PhD
<b>Scientific Director</b>	Richard Kaderman, PhD
<b>Senior Director, Medical Affairs</b>	Aviva Asnis-Alibozek, PA-C, MPAS
<b>Writer</b>	Douglas Paley
<b>Continuing Education Administrator for Nursing</b>	Sally Bogert, ARNP, WHCNP-BC
<b>Lead Nurse Planner</b>	Julia Aucoin, DNS, RN-BC, CNE
<b>Content Validation</b>	Margaret Peng Clayton Campbell Gloria Kelly, PhD
<b>Director, Creative and Copy Editing</b>	Aura Herrmann
<b>Creative Manager</b>	Fernando Rendina
<b>Graphic Designers</b>	Jessica Benitez Jason Cunnius Tamara Dabney Deepti Nath
<b>Senior Production Editor</b>	Alexis Oneca
<b>Traffic Manager</b>	Tere Sosa
<b>Copy Editors</b>	Dave Amber Margo Harris David Hill Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke
<b>Production Manager</b>	Tracy Potter
<b>Audio Production</b>	Frank Cesarano
<b>Web Master</b>	John Ribeiro
<b>Faculty Relations Manager</b>	Melissa Vives
<b>Contact Information</b>	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: <a href="mailto:DrNeilLove@ResearchToPractice.com">DrNeilLove@ResearchToPractice.com</a>
<b>For CME/CNE Information</b>	Email: <a href="mailto:CE@ResearchToPractice.com">CE@ResearchToPractice.com</a>

Copyright © 2010 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

# Breast Cancer<sup>®</sup>

U P D A T E

Copyright © 2010 Research To Practice.

This program is supported by educational grants from  
Genentech BioOncology and Genomic Health Inc.

## Research To Practice<sup>®</sup>

Sponsored by Research To Practice.

Last review date: July 2010

Release date: July 2010

Expiration date: July 2011

Contact hours: 2.5